SHIRE ACQUIRES FORESIGHT BIOTHERAPEUTICS FOR $300MN Shire to Buy Foresight Biotherapeutics for $300 Million Shire PLC has agreed to buy a privately held eye-drug company for $300 million in a deal that would add another promising ophthalmology treatment...